...Takefumi Matsuo; Miyako Matsuo; Takaki Sugimoto; Keiko Wanaka Heparin-induced thrombocytopenia (HIT) is known to complicate disseminated intravascular coagulation (DIC), but rarely to be complicated by DIC. We measured the titers of anti-PF4/hepatin complex antibodies by ELISA (HIT-Elisa...

...B.H. Chong; H.N. Magnani Patients who develop heparin-induced thrombocytopenia (HIT) frequently need further anticoagulation to treat an ongoing thromboembolic problem or to prevent one. Orgaran (Org 10172), a low-molecular-weight (LMW) glycosaminoglycuronan, has shown a low frequency (10...

...M. Gouault-Heilmann; Y. Huet; S. Adnot; G. Contant; F. Bonnet; L. Intrator; D. Payen; M. Levent Eight patients with a delayed-onset heparin-induced thrombocytopenia, with thrombotic complications requiring immediate anticoagulation in 7 of them, were given low molecular weight heparin (LMWH...

...Takefumi Matsuo; Shunji Suzuki; Miyako Matsuo; Hiroko Kobayasi Preexisting heparin-induced thrombocytopenia (HIT) antibodies are detected in some patients who have not previously been exposed to any kind of heparin. However, the role of preexisting HIT antibodies in acute coronary syndrome (ACS...

.... A large-scale study with bivalirudin in patients with acute MI (the HERO-2 trial) has not shown a reduction in mortality but a 30% reduction of reinfarction within 96 h. Hirudin and argatroban have been successfully used in patients with heparin-induced thrombocytopenia type II. Several orally active...